Nabriva Therapeutics plc [NASDAQ: NBRV] slipped around -0.47 points on Monday, while shares priced at $1.92 at the close of the session, down -19.67%. The company report on March 1, 2021 that Nabriva Therapeutics Announces $25.4 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules.
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that it has entered into a definitive agreement with certain healthcare-focused and institutional investors for the purchase and sale of (i) an aggregate of 10,361,010 ordinary shares (or pre-funded warrants in lieu thereof) and (ii) warrants to purchase up to an aggregate of 5,180,505 ordinary shares in a registered direct offering priced at-the-market under Nasdaq rules. Each ordinary share and accompanying warrant are being sold together at a combined purchase price of $2.4525, and each pre-funded warrant and accompanying warrant are being sold together at a combined purchase price of $2.4425. The warrants have an exercise price of $2.39 per share, are exercisable on the issuance date and will expire on the five-year anniversary of the issuance date.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
Nabriva Therapeutics plc stock is now -20.66% down from its year-to-date (YTD) trading value. NBRV Stock saw the intraday high of $2.05 and lowest of $1.84 per share. The company’s 52-week high price is 16.20, which means current price is +4.35% above from all time high which was touched on 02/10/21.
Compared to the average trading volume of 1.10M shares, NBRV reached a trading volume of 15922110 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Nabriva Therapeutics plc [NBRV]?
Wedbush have made an estimate for Nabriva Therapeutics plc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on March 19, 2020. The new note on the price target was released on May 02, 2019, representing the official price target for Nabriva Therapeutics plc stock. Previously, the target price had yet another drop from $9 to $7, while H.C. Wainwright kept a Buy rating on NBRV stock.
The Average True Range (ATR) for Nabriva Therapeutics plc is set at 0.27, with the Price to Sales ratio for NBRV stock in the period of the last 12 months amounting to 14.08. The Price to Book ratio for the last quarter was 0.77, with the Price to Cash per share for the same quarter was set at 1.93.
How has NBRV stock performed recently?
Nabriva Therapeutics plc [NBRV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -31.43. With this latest performance, NBRV shares dropped by -29.93% in over the last four-week period, additionally sinking by -68.52% over the last 6 months – not to mention a drop of -85.78% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NBRV stock in for the last two-week period is set at 24.56, with the RSI for the last a single of trading hit 16.85, and the three-weeks RSI is set at 29.71 for Nabriva Therapeutics plc [NBRV]. The present Moving Average for the last 50 days of trading for this stock 2.7782, while it was recorded at 2.3680 for the last single week of trading, and 5.3604 for the last 200 days.
Nabriva Therapeutics plc [NBRV]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Nabriva Therapeutics plc [NBRV] shares currently have an operating margin of -838.40 and a Gross Margin at +91.14. Nabriva Therapeutics plc’s Net Margin is presently recorded at -872.95.
Return on Total Capital for NBRV is now -94.56, given the latest momentum, and Return on Invested Capital for the company is -98.46. Return on Equity for this stock declined to -150.61, with Return on Assets sitting at -80.93. When it comes to the capital structure of this company, Nabriva Therapeutics plc [NBRV] has a Total Debt to Total Equity ratio set at 83.59. Additionally, NBRV Total Debt to Total Capital is recorded at 45.53, with Total Debt to Total Assets ending up at 36.66. Long-Term Debt to Equity for the company is recorded at 83.59, with the Long-Term Debt to Total Capital now at 45.53.
Reflecting on the efficiency of the workforce at the company, Nabriva Therapeutics plc [NBRV] managed to generate an average of -$510,889 per employee. Receivables Turnover for the company is 2.34 with a Total Asset Turnover recorded at a value of 0.09.Nabriva Therapeutics plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.40 and a Current Ratio set at 4.90.
Earnings analysis for Nabriva Therapeutics plc [NBRV]
With the latest financial reports released by the company, Nabriva Therapeutics plc posted -2.9/share EPS, while the average EPS was predicted by analysts to be reported at -3.32/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 12.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NBRV.
Insider trade positions for Nabriva Therapeutics plc [NBRV]
There are presently around $6 million, or 22.60% of NBRV stock, in the hands of institutional investors. The top three institutional holders of NBRV stocks are: FMR LLC with ownership of 1,429,259, which is approximately New of the company’s market cap and around 1.80% of the total institutional ownership; FRAZIER MANAGEMENT LLC, holding 425,650 shares of the stock with an approximate value of $0.82 million in NBRV stocks shares; and MORGAN STANLEY, currently with $0.76 million in NBRV stock with ownership of nearly New of the company’s market capitalization.
Positions in Nabriva Therapeutics plc stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 30 institutional holders increased their position in Nabriva Therapeutics plc [NASDAQ:NBRV] by around 3,370,711 shares. Additionally, 0 investors decreased positions by around 0 shares, while 0 investors held positions by with 0 shares. The mentioned changes placed institutional holdings at 3,370,711 shares, according to the latest SEC report filing. NBRV stock had 30 new institutional investments in for a total of 3,370,711 shares, while 0 institutional investors sold positions of 0 shares during the same period.